{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:44:58Z","timestamp":1788432298322,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":96,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006388","name":"Geneva University Hospitals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006388","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ijantimicag.2022.106601","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T05:05:01Z","timestamp":1651813501000},"page":"106601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Therapeutic drug monitoring and clinical outcomes in severely ill patients receiving amoxicillin: a single-centre prospective cohort study"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2016-6759","authenticated-orcid":false,"given":"Christophe","family":"Marti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Stirnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Lescuyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tonoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"von Dach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Huttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2022.106601_bib0001","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijantimicag.2014.12.017","article-title":"Augmented renal clearance, low \u03b2-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study","volume":"45","author":"Huttner","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2022.106601_bib0002","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40265-018-0880-z","article-title":"Therapeutic drug monitoring of \u03b2-lactams and other antibiotics in the intensive care unit: which agents, which patients and which infections?","volume":"78","author":"Muller","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2022.106601_bib0003","first-page":"83","article-title":"Obesity in America","volume":"19","author":"Menifield","year":"2008","journal-title":"ABNF J"},{"key":"10.1016\/j.ijantimicag.2022.106601_bib0004","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1128\/JCM.01553-14","article-title":"Genomic load from sputum samples and nasopharyngeal swabs for diagnosis of pneumococcal pneumonia in HIV-infected adults","volume":"52","author":"Albrich","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2022.106601_bib0005","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/jac\/dkt523","article-title":"An international, multicentre survey of \u03b2-lactam antibiotic therapeutic drug monitoring practice in intensive care units","volume":"69","author":"Wong","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106601_bib0006","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.cmi.2016.04.019","article-title":"The ANTIBIOPERF study: a nationwide cross-sectional survey about practices for \u03b2-lactam administration and therapeutic drug monitoring among critically ill patients in France","volume":"22","author":"Charmillon","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2022.106601_bib0007","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cmi.2017.01.005","article-title":"Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study","volume":"23","author":"Huwyler","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2022.106601_bib0008","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cmi.2018.11.020","article-title":"Therapeutic drug monitoring of imipenem and the incidence of toxicity and failure in hospitalized patients: a retrospective cohort study","volume":"25","author":"Bricheux","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2022.106601_bib0009","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0","year":"2010"},{"key":"10.1016\/j.ijantimicag.2022.106601_bib0010","unstructured":"Uppsala Monitoring Centre (UMC). The use of the WHO-UMC system for standardised case causality assessment. http:\/\/who-umc.org\/Graphics\/24734.pdf [accessed 10 May 2022]."},{"key":"10.1016\/j.ijantimicag.2022.106601_bib0011","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/11530350-000000000-00000","article-title":"Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case\u2013control study in Italy","volume":"33","author":"Bertuola","year":"2010","journal-title":"Drug Saf"},{"key":"10.1016\/j.ijantimicag.2022.106601_bib0012","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1310\/hpj4910-956","article-title":"Amoxicillin\/clavulanic acid-induced thrombocytopenia","volume":"49","author":"Mansour","year":"2014","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.ijantimicag.2022.106601_bib0013","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13054-016-1255-z","article-title":"Piperacillin concentration in relation to therapeutic range in critically ill patients\u2014a prospective observational study","volume":"20","author":"Zander","year":"2016","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2022.106601_bib0014","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/2050-6511-15-38","article-title":"Is the standard dose of amoxicillin\u2013clavulanic acid sufficient?","volume":"15","author":"Haeseker","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.ijantimicag.2022.106601_bib0015","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2022.106601_bib0016","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2022.106601_bib0017","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/jac\/dks468","article-title":"Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia","volume":"68","author":"Muller","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106601_bib0018","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2110-5820-2-35","article-title":"Does \u03b2-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review","volume":"2","author":"Sime","year":"2012","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.ijantimicag.2022.106601_bib0019","doi-asserted-by":"crossref","first-page":"w20110","DOI":"10.4414\/smw.2019.20110","volume":"149","author":"Zanichelli","year":"2019","journal-title":"Swiss Med Wkly"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922001108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922001108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:42:53Z","timestamp":1760377373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857922001108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0924857922001108"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106601","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic drug monitoring and clinical outcomes in severely ill patients receiving amoxicillin: a single-centre prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106601"}}